SENSEI BIOTHERAPEUTICS INC (SNSE)
US81728A1088 - Common Stock
Overall SNSE gets a fundamental rating of 1 out of 10. We evaluated SNSE against 561 industry peers in the Biotechnology industry. While SNSE seems to be doing ok healthwise, there are quite some concerns on its profitability. SNSE has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
SNSE had negative earnings in the past year.
In the past year SNSE has reported a negative cash flow from operations.
In the past 5 years SNSE always reported negative net income.
In the past 5 years SNSE always reported negative operating cash flow.
1.2 Ratios
SNSE's Return On Assets of -55.96% is in line compared to the rest of the industry. SNSE outperforms 43.60% of its industry peers.
SNSE has a Return On Equity (-65.10%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.96% | ||
| ROE | -65.1% | ||
| ROIC | N/A |
ROA(3y)-36.97%
ROA(5y)-383.39%
ROE(3y)-41.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SNSE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, SNSE has less shares outstanding
Compared to 5 years ago, SNSE has less shares outstanding
Compared to 1 year ago, SNSE has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -6.72, we must say that SNSE is in the distress zone and has some risk of bankruptcy.
SNSE has a Altman-Z score of -6.72. This is in the lower half of the industry: SNSE underperforms 68.65% of its industry peers.
SNSE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
SNSE's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. SNSE outperforms 46.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.72 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
SNSE has a Current Ratio of 8.84. This indicates that SNSE is financially healthy and has no problem in meeting its short term obligations.
SNSE's Current ratio of 8.84 is fine compared to the rest of the industry. SNSE outperforms 76.04% of its industry peers.
A Quick Ratio of 8.84 indicates that SNSE has no problem at all paying its short term obligations.
SNSE's Quick ratio of 8.84 is fine compared to the rest of the industry. SNSE outperforms 76.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.84 | ||
| Quick Ratio | 8.84 |
3. Growth
3.1 Past
SNSE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.85%, which is quite good.
EPS 1Y (TTM)9.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
SNSE is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.75% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.12%
EPS Next 2Y9.84%
EPS Next 3Y9.19%
EPS Next 5Y-2.75%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SNSE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNSE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.84%
EPS Next 3Y9.19%
5. Dividend
5.1 Amount
SNSE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SENSEI BIOTHERAPEUTICS INC
NASDAQ:SNSE (1/6/2025, 5:29:33 PM)
After market: 0.5359 +0.01 (+1.8%)0.5264
+0.02 (+4.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners8.45%
Inst Owner Change0%
Ins Owners2.24%
Ins Owner Change0%
Market Cap13.24M
Analysts89.09
Price Target4.21 (699.77%)
Short Float %0.51%
Short Ratio0.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.93%
Min EPS beat(2)4.85%
Max EPS beat(2)9.02%
EPS beat(4)3
Avg EPS beat(4)1.05%
Min EPS beat(4)-14.08%
Max EPS beat(4)9.02%
EPS beat(8)7
Avg EPS beat(8)5.29%
EPS beat(12)9
Avg EPS beat(12)3.57%
EPS beat(16)10
Avg EPS beat(16)-1.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.61%
EPS NY rev (1m)-1.24%
EPS NY rev (3m)-3.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.29 | ||
| P/tB | 0.29 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0
BVpS1.82
TBVpS1.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.96% | ||
| ROE | -65.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-36.97%
ROA(5y)-383.39%
ROE(3y)-41.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 11.04% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.84 | ||
| Quick Ratio | 8.84 | ||
| Altman-Z | -6.72 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)110.41%
Cap/Depr(5y)195.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.57%
EPS Next Y4.12%
EPS Next 2Y9.84%
EPS Next 3Y9.19%
EPS Next 5Y-2.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.27%
EBIT Next 3Y1.26%
EBIT Next 5YN/A
FCF growth 1Y34.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.9%
OCF growth 3YN/A
OCF growth 5YN/A